Discovering DiabLO: A Potential Drug Target Or Biomarker (G56616)

Target Name: DIABLO

NCBI ID: G56616

Discovering DiabLO: A Potential Drug Target Or Biomarker

DiabLO (diablo Inactivating Asset binding Mitochondrial Protein) is a protein that is expressed in the mitochondria, which are organelles responsible for generating energy in the cell. It is a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

The discovery of DiabLO was made by a team of researchers at the University of California, San Diego, led by Dr. Zephyr Papula. The researchers identified the protein as a potential drug target by studying its structure and function.

The protein is named after the DiabLO gene, which encodes the protein. It is a 21-kDa protein that is expressed in the mitochondria. The protein is composed of two distinct regions: an N-terminal region that contains a nucleotide-binding oligomerization domain (NBD), and a C-terminal region that contains a transmembrane domain (TMD) and a putative intramolecular signaling region (IMSR).

The NBD region is the protein's most well-known feature. It contains a nucleotide-binding oligomerization domain (NBD), which is a protein-coding region that can bind to specific nucleotides in the DNA. This domain is known for its ability to interact with DNA in a specific way, which may influence the function and activity of the protein.

The C-terminal region of DiabLO contains a transmembrane domain (TMD) and a putative intramolecular signaling region (IMSR). The TMD is a region that forms the boundary between the cytoplasm and the mitochondria, while the IMSR is a region that may play a role in the regulation of mitochondrial function.

Studies have shown that DiabLO is involved in a variety of cellular processes, including metabolism, cell growth, and stress response. It is also involved in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

One of the potential benefits of targeting DiabLO as a drug or biomarker is that it is thought to have a relatively low risk of adverse effects. This is because the protein is primarily expressed in the mitochondria, which are not involved in the production of most drugs . Additionally, because the protein is primarily localized to the mitochondria, it is not expected to have a significant impact on the body's overall system.

Another potential benefit of targeting DiabLO is that it is thought to be involved in a variety of signaling pathways that are involved in the development and progression of disease. For example, studies have shown that DiabLO is involved in the regulation of cell growth, metabolism, and stress response. Additionally, it is thought to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Targeting DiabLO as a drug or biomarker also has the potential to lead to new insights into the underlying mechanisms of these diseases. For example, studies have shown that DiabLO is involved in the regulation of the production of reactive oxygen species (ROS), which are thought to play a role in the development and progression of neurodegenerative diseases. Additionally, targeting DiabLO as a drug or biomarker may also lead to the development of new diagnostic tools for these diseases.

In conclusion, DiabLO is a protein that is expressed in the mitochondria and is involved in a variety of cellular processes, including metabolism, cell growth, and stress response. It is also thought to be involved in the development and progression of a variety of diseases , including cancer, neurodegenerative diseases, and metabolic disorders. As a potential drug target or biomarker, DiabLO is the focus of ongoing research in the field of molecular biology and may have the potential to lead to new insights into the underlying mechanisms of these diseases and the development of new treatments.

Protein Name: Diablo IAP-binding Mitochondrial Protein

Functions: Promotes apoptosis by activating caspases in the cytochrome c/Apaf-1/caspase-9 pathway. Acts by opposing the inhibitory activity of inhibitor of apoptosis proteins (IAP). Inhibits the activity of BIRC6/bruce by inhibiting its binding to caspases. Isoform 3 attenuates the stability and apoptosis-inhibiting activity of XIAP/BIRC4 by promoting XIAP/BIRC4 ubiquitination and degradation through the ubiquitin-proteasome pathway. Isoform 3 also disrupts XIAP/BIRC4 interacting with processed caspase-9 and promotes caspase-3 activation. Isoform 1 is defective in the capacity to down-regulate the XIAP/BIRC4 abundance

More Common Targets